SillaJen announced on Wednesday that two research studies on its developmental cancer drug BAL0891 have been accepted for poster presentation at the American Association for Cancer Research (AACR) 2026 conference.
The AACR is widely recognized as one of the world’s top three cancer conferences, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). This year’s event is scheduled to take place from April 17 to 22 in San Diego, California.
One of the accepted studies, titled, Mutation-dependent sensitivity to the dual TTK/PLK1 inhibitor BAL0891 in patient-derived gastric cancer organoids, was submitted by Dr. Ra Sun-young from Yonsei University College of Medicine.
This research evaluates how BAL0891 performs in patient-derived gastric cancer organoid models.
The second study, Dual TTK/PLK1 inhibition combined with G-CSF treatment synergistically suppresses metastatic progression in triple-negative breast cancer, was submitted by Dr. Lee Jung-yeon from Hanyang University College of Medicine. This study examined the combined effects of BAL0891 and G-CSF in a triple-negative breast cancer model.
A spokesperson for SillaJen stated that the AACR presentation will showcase various preclinical research findings related to BAL0891. It intends to continue assessing BAL0891’s therapeutic potential in conjunction with ongoing clinical trials.
